IMPORTANCE: The failure or success of radical treatment in patients with head and neck squamous cell carcinoma (HNSCC) is associated with many known and unknown factors; hence, there is a search for further prognostic markers to help optimize therapeutic strategy and improve treatment outcomes. OBJECTIVE: To assess the association of programmed cell death ligand 1 (PD-L1) expression on immune or tumor cells, including its composite expression on both cell types, with overall survival (OS) or specific survival. DATA SOURCES: MEDLINE, Embase, PQSciTech, and HCAPlus databases were systematically searched for cohort studies focused on the prognostic role of PD-L1 expression in patients with HNSCC in curative stages of the disease. Search results generated publications from January 1, 2010, to January 6, 2023. STUDY SELECTION: Of 3825 publications identified, a total of 17 cohort studies in the English language met inclusion criteria of this systematic review and meta-analysis. Eligible studies reported adjusted hazard ratios (aHRs) with 95% CIs for the association of PD-L1 expression levels with OS and arbitrary specific survival. DATA EXTRACTION AND SYNTHESIS: Data from studies were extracted independently by 2 researchers strictly adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines and recommendations. The risk of bias was assessed using the Quality in Prognosis Studies tool and Newcastle-Ottawa Scale. Pooled effect estimates were obtained using a random-effect or fixed-effect model based on homogeneity of studies. MAIN OUTCOMES AND MEASURES: The primary outcome was to investigate whether there was an association between PD-L1 expression on immune or tumor cells and OS. RESULTS: In 17 cohort studies of the association of PD-L1 expression with survival in 3190 patients with HNSCC, high PD-L1 expression on immune cells was associated with a favorable OS (pooled aHR, 0.39; 95% CI, 0.25-0.59). There was no association between composite PD-L1 expression on immune and tumor cells and OS (pooled aHR, 0.79; 95% CI, 0.55-1.14) or between PD-L1 expressed only on tumor cells and OS (pooled aHR, 1.22; 95% CI, 0.87-1.70). A high level of PD-L1 expression on immune cells was associated with favorable specific survival (pooled aHR, 0.52; 95% CI, 0.38-0.72). There were no interactions between tumor location or type of primary treatment (ie, surgery vs radiotherapy or radiochemotherapy) and the association between PD-L1 expression and OS. CONCLUSIONS AND RELEVANCE: This study's findings suggest that PD-L1 expression on immune cells may serve as a new prognostic biomarker in patients with HNSCC. However, future studies may be warranted to verify this potential role given the limited number of studies on this topic conducted and published to date.

Department of Epidemiology and Biostatistics 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Oncology Královské Vinohrady University Hospital Prague Czech Republic

Department of Oncology Ostrava University Hospital Ostrava Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591-5596. doi:10.1242/jcs.116392 PubMed DOI

Curry JM, Sprandio J, Cognetti D, et al. . Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol. 2014;41(2):217-234. doi:10.1053/j.seminoncol.2014.03.003 PubMed DOI

Binnewies M, Roberts EW, Kersten K, et al. . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x PubMed DOI PMC

Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 2013;6(2):123-133. doi:10.1007/s12307-012-0127-6 PubMed DOI PMC

Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261-267. doi:10.1016/j.coi.2013.03.004 PubMed DOI

Mei Z, Liu Y, Liu C, et al. . Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(6):1595-1605. doi:10.1038/bjc.2014.46 PubMed DOI PMC

Mahmoud SMA, Paish EC, Powe DG, et al. . Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-1955. doi:10.1200/JCO.2010.30.5037 PubMed DOI

Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93-103. doi:10.1038/bjc.2011.189 PubMed DOI PMC

Uppaluri R, Dunn GP, Lewis JS Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:16. PubMed PMC

Alsaab HO, Sau S, Alzhrani R, et al. . PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.00561 PubMed DOI PMC

Rühle A, Todorovic J, Spohn SSK, et al. . Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy. Radiat Oncol. 2022;17(1):181. doi:10.1186/s13014-022-02153-9 PubMed DOI PMC

Quan H, Liu S, Shan Z, et al. . Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis. Arch Oral Biol. 2020;119:104916. doi:10.1016/j.archoralbio.2020.104916 PubMed DOI

de Vicente JC, Rodríguez-Santamarta T, Rodrigo JP, Blanco-Lorenzo V, Allonca E, García-Pedrero JM. PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28(3):546-554. doi:10.1158/1055-9965.EPI-18-0779 PubMed DOI

Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-286. doi:10.7326/0003-4819-158-4-201302190-00009 PubMed DOI

Wells GA, Shea B, O’Connell D, et al. . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed December 11, 2022. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Simmonds M. Quantifying the risk of error when interpreting funnel plots. Syst Rev. 2015;4(1):24. doi:10.1186/s13643-015-0004-8 PubMed DOI PMC

Xie S, Xu H, Shan X, Liu B, Wang K, Cai Z. Clinicopathological and prognostic significance of survivin expression in patients with oral squamous cell carcinoma: evidence from a meta-analysis. PLoS One. 2015;10(2):e0116517. doi:10.1371/journal.pone.0116517 PubMed DOI PMC

Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046-1055. doi:10.1016/S0895-4356(01)00377-8 PubMed DOI

Fukushima Y, Someya M, Nakata K, et al. . Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Radiother Oncol. 2018;129(2):409-414. doi:10.1016/j.radonc.2018.08.023 PubMed DOI

Kim HR, Ha SJ, Hong MH, et al. . PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6(1):36956. doi:10.1038/srep36956 PubMed DOI PMC

Sato F, Ono T, Kawahara A, et al. . Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol. 2019;72(8):542-549. doi:10.1136/jclinpath-2019-205818 PubMed DOI PMC

Balermpas P, Rödel F, Krause M, et al. ; DKTK-ROG . The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: a multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer. 2017;141(3):594-603. doi:10.1002/ijc.30770 PubMed DOI

Sanchez-Canteli M, Granda-Díaz R, Del Rio-Ibisate N, et al. . PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas. Cancer Immunol Immunother. 2020;69(10):2089-2100. doi:10.1007/s00262-020-02604-w PubMed DOI PMC

Lilja-Fischer JK, Eriksen JG, Georgsen JB, et al. . Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. Acta Oncol. 2020;59(6):666-672. doi:10.1080/0284186X.2020.1729407 PubMed DOI

Ngamphaiboon N, Chureemas T, Siripoon T, et al. . Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Med Oncol. 2019;36(2):21. doi:10.1007/s12032-018-1241-1 PubMed DOI

Peña-Cardelles JF, Pozo-Kreilinger JJ, Roncador G, et al. . Prognosis value of immunoregulatory molecules in oral cancer microenvironment: an immunohistochemical study. Biomedicines. 2022;10(3):710. doi:10.3390/biomedicines10030710 PubMed DOI PMC

Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH. Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018;47(5):568-577. doi:10.1016/j.ijom.2017.09.006 PubMed DOI

Hong AM, Vilain RE, Romanes S, et al. . PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. Oncotarget. 2016;7(47):77010-77020. doi:10.18632/oncotarget.12776 PubMed DOI PMC

Zhou AL, Wang X, Yu W, et al. . Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. Pathol Res Pract. 2020;216(9):153093. doi:10.1016/j.prp.2020.153093 PubMed DOI

Lyu X, Zhang M, Li G, Jiang Y, Qiao Q. PD-1 and PD-L1 expression predicts radiosensitivity and clinical outcomes in head and neck cancer and is associated with HPV infection. J Cancer. 2019;10(4):937-948. doi:10.7150/jca.27199 PubMed DOI PMC

Lin YM, Sung WW, Hsieh MJ, et al. . High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One. 2015;10(11):e0142656. doi:10.1371/journal.pone.0142656 PubMed DOI PMC

Fu ZM, Zhang DJ, Guo YY, et al. . Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma. Mol Clin Oncol. 2022;16(3):59. doi:10.3892/mco.2022.2492 PubMed DOI PMC

Adamski ŁJ, Starzyńska A, Adamska P, et al. . High PD-L1 expression on tumor cells indicates worse overall survival in advanced oral squamous cell carcinomas of the tongue and the floor of the mouth but not in other oral compartments. Biomedicines. 2021;9(9):1132. doi:10.3390/biomedicines9091132 PubMed DOI PMC

Yang F, Zeng Z, Li J, Zheng Y, Wei F, Ren X. PD-1/PD-L1 axis, rather than high-mobility group alarmins or CD8+ tumor-infiltrating lymphocytes, is associated with survival in head and neck squamous cell carcinoma patients who received surgical resection. Front Oncol. 2018;8:604. doi:10.3389/fonc.2018.00604 PubMed DOI PMC

Schneider S, Kadletz L, Wiebringhaus R, et al. . PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis—impact on clinical outcome. Histopathology. 2018;73(4):573-584. doi:10.1111/his.13646 PubMed DOI

Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2018;86:81-90. doi:10.1016/j.oraloncology.2018.09.016 PubMed DOI

Li J, Wang P, Xu Y. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: a systematic review and meta-analysis. PLoS One. 2017;12(6):e0179536. doi:10.1371/journal.pone.0179536 PubMed DOI PMC

Troiano G, Caponio VCA, Zhurakivska K, et al. . High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: a meta-analysis of the literature. Cell Prolif. 2019;52(2):e12537. doi:10.1111/cpr.12537 PubMed DOI PMC

Tang H, Zhou X, Ye Y, Zhou Y, Wu C, Xu Y. The different role of PD-L1 in head and neck squamous cell carcinomas: a meta-analysis. Pathol Res Pract. 2020;216(1):152768. doi:10.1016/j.prp.2019.152768 PubMed DOI

Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-García P. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: a systematic review and comprehensive meta-analysis. Oral Oncol. 2020;106:104722. doi:10.1016/j.oraloncology.2020.104722 PubMed DOI

High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study